Integrin αL/ITGAL/CD11a Antibody (CRIS-3): sc-59741

Integrin αL Antibody (CRIS-3) is a mouse monoclonal IgG2b antibody that detects Integrin αL in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). Integrin αL, also called CD11a, is a crucial component of the immune system, primarily expressed on leukocytes, where anti-Integrin αL antibody (CRIS-3) plays a vital role in mediating cell adhesion and migration. Integrin αL is essential for the immune response, as Integrin αL facilitates the interaction between leukocytes and other cells, including endothelial cells, during inflammation and immune surveillance. The structure of Integrin αL, which consists of a large extracellular domain, a single transmembrane domain, and a short cytoplasmic tail, allows for the binding of various ligands, such as intercellular adhesion molecules (ICAMs). This binding is critical for leukocyte trafficking to sites of infection or injury, thereby influencing the overall effectiveness of the immune response. Integrin αL monoclonal antibody (CRIS-3) is an invaluable tool for researchers studying immune cell behavior, signaling pathways, and the mechanisms underlying various inflammatory diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Integrin αL/ITGAL/CD11a Antibody (CRIS-3) References:

1. Polyomavirus enhancer-binding protein 2/core binding factor/acute myeloid leukemia factors contribute to the cell type-specific activity of the CD11a integrin gene promoter.  |  Puig-Kröger, A., et al. 2000. J Biol Chem. 275: 28507-12. PMID: 10882733
2. Effect of integrin beta 2 subunit truncations on LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18) assembly, surface expression, and function.  |  Tan, SM., et al. 2000. J Immunol. 165: 2574-81. PMID: 10946284
3. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation.  |  Vincenti, F., et al. 2007. Am J Transplant. 7: 1770-7. PMID: 17564637
4. RFX1 regulates CD70 and CD11a expression in lupus T cells by recruiting the histone methyltransferase SUV39H1.  |  Zhao, M., et al. 2010. Arthritis Res Ther. 12: R227. PMID: 21192791
5. Treatment of inflammatory macular edema with humanized anti-CD11a antibody therapy.  |  Faia, LJ., et al. 2011. Invest Ophthalmol Vis Sci. 52: 6919-24. PMID: 21498606
6. COVID-19-Induced ARDS Is Associated with Decreased Frequency of Activated Memory/Effector T Cells Expressing CD11a+.  |  Anft, M., et al. 2020. Mol Ther. 28: 2691-2702. PMID: 33186542
7. Triple knockdown of CD11a, CD49d, and PSGL1 in T cells reduces CAR-T cell toxicity but preserves activity against solid tumors in mice.  |  Wang, H., et al. 2025. Sci Transl Med. 17: eadl6432. PMID: 39841806
8. Transient depletion of T cells with bright CD11a/CD18 expression from peripheral circulation during acute Kawasaki disease.  |  Furukawa, S., et al. 1993. Scand J Immunol. 37: 377-80. PMID: 8095103
9. Identification of Sp1-binding sites in the CD11c (p150,95 alpha) and CD11a (LFA-1 alpha) integrin subunit promoters and their involvement in the tissue-specific expression of CD11c.  |  López-Rodríguez, C., et al. 1995. Eur J Immunol. 25: 3496-503. PMID: 8566043
10. Engagement of adhesion molecules (CD18, CD11a, CD45, CD44, and CD58) enhances human immunodeficiency virus type 1 replication in monocytic cells through a tumor necrosis factor-modulated pathway.  |  Shattock, RJ., et al. 1996. J Infect Dis. 174: 54-62. PMID: 8656013

The preferred Integrin αL/ITGAL/CD11a antibody is Integrin αL/ITGAL/CD11a Antibody (E-1): sc-374172.